{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:49:54Z","timestamp":1787989794170,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2025-511"],"award-info":[{"award-number":["075-15-2025-511"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["FSEG-2025-0007"],"award-info":[{"award-number":["FSEG-2025-0007"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2025-210"],"award-info":[{"award-number":["075-15-2025-210"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijbiomac.2025.148372","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:11:56Z","timestamp":1760998316000},"page":"148372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Oral delivery of PARP inhibitor via gelatin- and chitosan-based nanocarriers for refined therapy of primary and metastatic melanomas"],"prefix":"10.1016","volume":"331","author":[{"given":"Anna","family":"Rogova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia A.","family":"Tishchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radmila R.","family":"Sergeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timofey E.","family":"Karpov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Gorbunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya V.","family":"Faizullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria S.","family":"Novikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei A.","family":"Shipilovskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Timin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.148372_bb0005","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8432","article-title":"Melanoma metastasis: what role does melanin play? (Review)","volume":"48","author":"Saud","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0010","doi-asserted-by":"crossref","DOI":"10.1586\/17469872.3.5.569","article-title":"Current concepts of metastasis in melanoma","volume":"3","author":"Zbytek","year":"2008","journal-title":"Expert Rev Dermatol"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0015","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2021-0001","article-title":"Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments","volume":"8","author":"Zhang","year":"2021","journal-title":"Melanoma Manag."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0059-7","article-title":"Cell death-based treatments of melanoma: conventional treatments and new therapeutic strategies review-article","volume":"9","author":"Mattia","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.05.015","article-title":"Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma","volume":"39","author":"Marin-Bejar","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.15.9053","article-title":"Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review","volume":"26","author":"Lotfi-Jam","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2009.10.003","article-title":"Targeted delivery of low molecular drugs using chitosan and its derivatives","volume":"62","author":"Park","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0040","article-title":"Recent advances in targeted nanoparticles drug delivery to melanoma","volume":"11","author":"Li","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0045","unstructured":"Targeted Therapy Drug List by Cancer Type - NCI, (n.d.). https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies\/approved-drug-list#targeted-therapy-approved-for-skin-cancer (accessed August 8, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020286","article-title":"Article parp1 as a marker of an aggressive clinical phenotype in cutaneous melanoma\u2014a clinical and an in vitro study","volume":"10","author":"Kupczyk","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0065","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S116063","article-title":"A novel nanoemulsion-based method to produce ultrasmall, water-dispersible nanoparticles from chitosan, surface modified with cell-penetrating peptide for oral delivery of proteins and peptides","volume":"12","author":"Barbari","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0070","doi-asserted-by":"crossref","DOI":"10.1007\/s12272-013-0257-5","article-title":"The osmotic stress response of split influenza vaccine particles in an acidic environment","volume":"37","author":"Choi","year":"2014","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0075","doi-asserted-by":"crossref","DOI":"10.7150\/thno.36281","article-title":"A nano-liposome formulation of the PARP inhibitor talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07617-7","article-title":"H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer","volume":"7","author":"Mazzucchelli","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0085","article-title":"Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer","volume":"30","author":"Vysyaraju","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0090","article-title":"Olaparib and doxorubicin co-loaded polypeptide nanogel for enhanced breast cancer therapy","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0095","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S186881","article-title":"Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment","volume":"13","author":"Baldwin","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0100","series-title":"Functional Chitosan: Drug Delivery and Biomedical Applications","article-title":"Application of chitosan in oral drug delivery","author":"Eftekhari","year":"2020"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092361","article-title":"Chitosan in oral drug delivery formulations: a review","volume":"15","author":"Sangnim","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0110","doi-asserted-by":"crossref","DOI":"10.1021\/acs.biomac.3c01021","article-title":"Chemical and structural engineering of gelatin-based delivery systems for therapeutic applications: a review","volume":"25","author":"Jia","year":"2024","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126573","article-title":"Using chitosan, hyaluronic acid, alginate, and gelatin-based smart biological hydrogels for drug delivery in oral mucosal lesions: a review","volume":"252","author":"Samiraninezhad","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2017.09.039","article-title":"2-Aminothiophene scaffolds: diverse biological and pharmacological attributes in medicinal chemistry","volume":"140","author":"Bozorov","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0125","doi-asserted-by":"crossref","DOI":"10.1007\/s13738-019-01813-0","article-title":"Synthesis and biological evaluation of novel hybrid compounds derived from gallic acid and the 2-aminothiophene derivatives","volume":"17","author":"Mahdavi","year":"2020","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0130","article-title":"Synthesis of some new thiophene-based compounds and evaluations of their cytotoxic activities","volume":"37","author":"Mehdhar","year":"2023","journal-title":"Bull. Chem. Soc. Ethiop."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0135","doi-asserted-by":"crossref","DOI":"10.32604\/oncologie.2021.018532","article-title":"Synthesis, pharmacological evaluation, and in-silico studies of thiophene derivatives","volume":"23","author":"Mishra","year":"2021","journal-title":"Oncologie"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114502","article-title":"Recent contribution of medicinally active 2-aminothiophenes: a privileged scaffold for drug discovery","volume":"238","author":"Duvauchelle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2016.09.026","article-title":"Evaluation of the antiproliferative activity of 2-amino thiophene derivatives against human cancer cells lines","volume":"84","author":"A.C. V\u00e9ras of Aguiar","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2017.07.005","article-title":"Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro","volume":"138","author":"Chang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116653","article-title":"Synthesis and evaluation of RNase L-binding 2-aminothiophenes as anticancer agents","volume":"58","author":"Hwang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0160","article-title":"Design, synthesis and biological evaluation of 3,5-disubstituted 2-amino thiophene derivatives as a novel class of antitumor agents","volume":"22","author":"Romagnoli","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300758","article-title":"A decade\u2019s overview of 2-aminothiophenes and their fused analogs as promising anticancer agents","volume":"357","author":"Darwish","year":"2024","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115325","article-title":"Synthesis of thieno[3,2-e]pyrrolo[1,2-a]pyrimidine derivatives and their precursors containing 2-aminothiophenes fragments as anticancer agents for therapy of pulmonary metastatic melanoma","volume":"254","author":"Rogova","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101537","article-title":"Modified desolvation method enables simple one-step synthesis of gelatin nanoparticles from different gelatin types with any bloom values","volume":"13","author":"Khramtsov","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0180","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1021\/acs.chemmater.2c01507","article-title":"Universal chelator-free radiolabeling of organic and inorganic-based nanocarriers with diagnostic and therapeutic isotopes for internal radiotherapy","volume":"34","author":"Karpov","year":"2022","journal-title":"Chem. Mater."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0185","doi-asserted-by":"crossref","DOI":"10.1080\/17425247.2024.2393244","article-title":"An investigation of nano- and micron-sized carriers based on calcium carbonate and polylactic acid for oral administration of siRNA","author":"Akhmetova","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114020","article-title":"Lecithin-modified hybrid nanocarriers for enhanced locoregional therapy of melanoma: influence of surface modification on therapeutic response","volume":"385","author":"Timin","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0195","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S124938","article-title":"The role of surface charge in the desolvation process of gelatin: implications in nanoparticle synthesis and modulation of drug release","volume":"12","author":"Ahsan","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0200","doi-asserted-by":"crossref","DOI":"10.1186\/s13036-024-00403-w","article-title":"Optimize the parameters for the synthesis by the ionic gelation technique, purification, and freeze-drying of chitosan-sodium tripolyphosphate nanoparticles for biomedical purposes","volume":"18","author":"Guti\u00e9rrez-Ru\u00edz","year":"2024","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0205","doi-asserted-by":"crossref","DOI":"10.1007\/s00449-011-0591-2","article-title":"Studies on the characteristics of drug-loaded gelatin nanoparticles prepared by nanoprecipitation","author":"Lee","year":"2012","journal-title":"Bioprocess Biosyst. Eng."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0210","doi-asserted-by":"crossref","DOI":"10.15406\/jnmr.2015.02.00018","article-title":"Gelatin nanoparticles as a delivery system for proteins","volume":"2","author":"Solanki","year":"2015","journal-title":"J. Nanomed. Res."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2004.09.007","article-title":"Preparation and antibacterial activity of chitosan nanoparticles","volume":"339","author":"Qi","year":"2004","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2011.01.006","article-title":"Preparation and characterization of magnetic chitosan nanoparticles and its application for Cu(II) removal","volume":"168","author":"Yuwei","year":"2011","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/S0378-5173(98)00027-1","article-title":"In vitro evaluation of the mucoadhesive properties of chitosan microspheres","volume":"166","author":"He","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2012.04.007","article-title":"Chitosan-based drug delivery systems","volume":"81","author":"Bernkop-Schn\u00fcrch","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0235","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1039\/D4BM00898G","article-title":"Hyaluronic acid-functionalized nanoparticles for ulcerative colitis-targeted therapy: a comparative study of oral administration and intravenous injection","volume":"12","author":"Liu","year":"2024","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0240","doi-asserted-by":"crossref","DOI":"10.37022\/jiaps.v9i1.565","article-title":"Polymeric nanoparticles for oral delivery of biopharmaceuticals: an overview","author":"Alagarsamy","year":"2024","journal-title":"J. Innov. Appl. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0245","doi-asserted-by":"crossref","DOI":"10.1080\/03639045.2021.1908334","article-title":"Formulation of chitosan coated nanoliposomes for the oral delivery of colistin sulfate: in vitro characterization, 99mTc-radiolabeling and in vivo biodistribution studies","volume":"47","author":"Aboumanei","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2009.09.004","article-title":"Biodegradation, biodistribution and toxicity of chitosan","volume":"62","author":"Kean","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081647","article-title":"The current state of the art in PARP inhibitor-based delivery nanosystems","volume":"14","author":"Cai","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/pr10071329","article-title":"Development of chitosan-coated PLGA-based nanoparticles for improved oral Olaparib delivery: in vitro characterization, and in vivo pharmacokinetic studies","volume":"10","author":"Anwer","year":"2022","journal-title":"Processes"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0265","doi-asserted-by":"crossref","first-page":"8461","DOI":"10.2147\/IJN.S181546","article-title":"Olaparib nanoparticles potentiated radiosensitization effects on lung cancer","volume":"13","author":"Wu","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1552386","article-title":"PARP inhibitors in melanoma treatment: potential, challenges, and future directions","volume":"15","author":"Anaeme","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2009.08.004","article-title":"Chitosan-based formulations for delivery of DNA and siRNA","volume":"62","author":"Mao","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-409X(01)00245-9","article-title":"Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells","volume":"54","author":"Vinogradov","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148372_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025089299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025089299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:37:34Z","timestamp":1777484254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025089299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":57,"alternative-id":["S0141813025089299"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148372","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral delivery of PARP inhibitor via gelatin- and chitosan-based nanocarriers for refined therapy of primary and metastatic melanomas","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"148372"}}